Within Reach: ChenAn Biotech Launches Next-Gen Benchtop Mass Cytometry System Lunarion Xiaohui

2022Year12Month26On [Date], Polaris Biology officially launched its next-generationDesktop-levelMass Cytometry SystemLunarion™, will be launched in 2023Officially commenced delivery in the year.

The Lunarion™ mass cytometry system condenses powerful capabilities into a more compact chassis, inheriting the Starion^®While delivering superior performance, it incorporates an automated sample injection module and a full-fluidic path automatic cleaning system, achieving miniaturization and desktop integration of mass cytometry products.

Regarding the original intention behind the development of Lunarion™, Dr. Wang Yuchong, CEO and R&D Director of Polaris Biology, stated: “Starion^®"The mass cytometry system achieves international leadership in single-cell analysis performance. We hope that Lunarion Xiaohui™ can enable mass cytometry technology to enter more laboratories with a more convenient, rapid, and sensitive approach."

Meanwhile, he also revealed the significance of the name Lunarion 宵晖™ and the美好愿景 it embodies: “Since ancient times, we Chinese have had a deep-rooted cultural attachment to the moon, with ‘Xiaohui’ being one of its elegant appellations. However, in antiquity, the moon remained an unattainable entity. With advances in modern human technology, we are now able to reach those once desirable yet inaccessible ideals. Through the name Lunarion 宵晖™, we wish to convey that Polaris Biology is committed to making mass cytometry—an internationally advanced technology—accessible to more users by delivering higher performance at lower costs, thereby rendering high-throughput single-cell analysis both aspirational and achievable.”

Polaris Biology is dedicated to providing users with powerful and user-friendly single-cell solutions. By combining high-throughput single-cell omics with advanced algorithms, we deeply analyze individualized differences and dynamic changes in the immune system, offering research- and clinical-grade products and services for elucidating the biological mechanisms of complex diseases, precise disease subtyping, companion diagnostics, and innovative therapies.

Currently, Polaris Biology has two fully self-developed mass cytometry systems under its portfolio: Starion^®and Lunarion Xiaohui™, which boasts internationally leading performance. Meanwhile, Polaris Biology provides researchers and clinicians with a comprehensive solution encompassing hardware, supporting reagents, and high-dimensional data visualization analysis kits, jointly advancing the application of mass cytometry in fields such as hematology, tumor immunology, infection immunology, autoimmunity, and neoantigens.